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Oral fluid is an easily available specimen for studying drug use in a
cohort or population. The prevalence of drugs in samples of oral fluid
is the same as the prevalence in blood if using equivalent cutoff con-
centrations. The cutoffs in oral fluid may be higher or lower than that
in blood in accordance with the median oral fluid-to-blood (OF/B)
concentration ratio, but it is also influenced by the skewness of the
distribution of OF/B ratios. The aim of this study was to determine
formulae for the estimation of equivalent cutoff concentrations in
oral fluid and blood for 12 commonly used illegal and medicinal psy-
choactive drugs when oral fluid was collected with Statsure
Saliva.SamplerTM. Paired samples from 4,080 persons were col-
lected and analyzed with chromatographic methods and mass spec-
troscopic detection. Regression formulae for the concentrations
corresponding to selected percentiles in oral fluid versus the same
concentration percentiles in blood were determined. The accuracy
when multiplying the cutoff thresholds in blood with the average and
median OF/B ratios to estimate equivalent cutoffs in oral fluid was
also investigated. Prevalence regression gave the most accurate
results. The regression formulae can be used to estimate equivalent
cutoff concentrations in oral fluid and blood.
Introduction
Oral ﬂuid (mixed saliva) is increasingly used for drug testing in
epidemiological studies of drug use. Oral ﬂuid can easily be col-
lected using commercially available sampling devices, and the
sampling time is just a few minutes (1). The sampling is less in-
trusive than sampling of blood, hair and urine; therefore, the par-
ticipation rate in epidemiological studies has been higher when
collecting oral ﬂuid than when collecting other biological speci-
mens. Recent studies have obtained refusal rates as low as 3–6%
when collecting oral ﬂuid (2–4), whereas previously reported
refusal rates were 24–60% when collecting blood samples
(5–7), 24% for urine samples (8) and 14–44% for hair samples
(8, 9); in addition, many had insufﬁcient hair for sampling.
Monetary incentives were offered in most of the studies collect-
ing blood, urine or hair.
A drug ﬁnding in oral ﬂuid is a strong indication of recent drug
intake, and a blood sample taken at the same time will usually
also be positive for the actual drug if using appropriate analytical
cutoff thresholds for both matrices (10). The collection of oral
ﬂuid is therefore an excellent tool for studying recent drug use
in a cohort or population; however, for most drugs the concen-
tration in oral ﬂuid cannot be used to accurately estimate the
drug concentration in blood for an individual because of large
interindividual variations in concentration ratios between oral
ﬂuid and blood (11–13). The calculated relative standard devia-
tions for oral ﬂuid-to-blood (OF/B) ratios are often 50–100%.
For a cohort of drug users, the statistical distribution of drug
concentrations in blood and in oral ﬂuid will reﬂect the use of
drugs by the individuals in the cohort. It is therefore expected
that the drug concentrations in samples of oral ﬂuid from the
cohort can be used to estimate data on blood drug concentra-
tions of the cohort.
If analyzing the samples of blood and oral ﬂuid from all indivi-
duals in the cohort, the number of positive drug ﬁndings in
blood and oral ﬂuid will not always be equal because drug con-
centrations are different in blood and oral ﬂuid and the analytical
methods might not be sufﬁciently sensitive to detect all positive
cases in both types of specimen. However, when using ‘equiva-
lent’ cutoff concentrations, this difference will be minimized or
eliminated. Equivalent cutoff concentrations mean that the
prevalence of drug concentrations above cutoff CB in blood will
be equal to that of drug concentrations above cutoff COF in oral
ﬂuid in the studied cohort. Equivalent cutoff thresholds also
imply that both specimens will, on average, be positive for a drug
for the same length of time following the intake of a single drug
dose. The equivalent cutoff concentration in oral ﬂuid may be
higher or lower than that in blood in accordance with the
median OF/B concentration ratio. Owing to interindividual var-
iations, equivalent cutoff concentrations should not be used for
assessing drug concentrations in oral ﬂuid from single indivi-
duals, only in cohorts of drug users.
We have previously found that multiplying the blood concen-
tration CB with the OF/B regression coefﬁcient (slope) or the
average OF/B ratio gives a rough estimate of the equivalent con-
centration COF in oral ﬂuid for amphetamine and tetrahydro-
cannabinol (THC) (14). The actual differences between
equivalent drug concentration cutoffs CB and COF are related not
only to the mean OF/B ratio, but also to the statistical distribu-
tion of OF/B ratios among drug users. Therefore, more accurate
estimates for equivalent cutoff concentrations of blood and oral
ﬂuid may be obtained by using prevalence regression of aggre-
gated population data (15) or a statistical simulation method
(14), which is a more challenging procedure.
In some previous cross-sectional studies of drug use, partici-
pants were asked to provide either a sample of blood or a sample
of oral ﬂuid (6, 16). Analytical results from blood and oral ﬂuid
samples were pooled and used to calculate the overall preva-
lence of drug use. In some previous case–control studies,
samples of blood were collected from cases and oral ﬂuid from
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controls (17–19). In those types of studies, equivalent cutoff
thresholds must be used in order to make sound estimations of
total drug prevalence or sound estimates of odds ratios in case–
control studies.
The aim of this study was to determine formulae for the esti-
mation of equivalent drug cutoff concentrations in whole blood
and oral ﬂuid collected with Statsure Saliva.SamplerTM.
Materials and methods
Samples
A total of 4,080 paired samples of whole blood and oral ﬂuid
were collected from drivers in Belgium (n ¼ 2750), Finland
(n ¼ 339), Italy (n ¼ 891) and Norway (n ¼ 100) during 2007–
2010. This cohort consisted partly of random drivers included in
a roadside survey of alcohol, drugs and driving; partly of injured
drivers admitted to the hospital after involvement in a trafﬁc ac-
cident and partly of drivers arrested by the police suspected for
drug driving. Samples of oral ﬂuid were collected using Statsure
Saliva.SamplerTM (Saliva Diagnostic Systems, Framingham, MA,
USA), whereas whole blood was sampled using tubes containing
potassium oxalate and sodium ﬂuoride. All paired samples of
blood and oral ﬂuid were collected within 30 min. Samples of
oral ﬂuid were stored at 2–88C for a maximum of 48 h and there-
after frozen at about 2208C until analyzed. Most drugs were
found to be stable in collected oral ﬂuid at 2–88C for a week
(20). For blood samples, handling and storage was done in ac-
cordance with local routines. In general, samples might have
been kept at ambient temperature between sampling and deliv-
ery to the analytical laboratory up to 3 days. When received by
the laboratory, samples were either frozen or stored at 2–88C for
up to 2 weeks before being frozen at about 2208C. The added
preservatives ensured that degradation was minimized.
Analytical methods
Samples of blood and oral ﬂuid were analyzed with high-
performance or ultra performance liquid chromatography or gas
chromatography with single or tandemmass spectrometric detec-
tion using validated analytical methods in Belgium (21), Norway
(22), Italy (23, 24) and Finland (25, 26) as previously described.
Only quantitative data above the limits of quantiﬁcation (LOQs)
for the participating countries (12) were included. Analytical ﬁnd-
ings for cocaine and oxazepam from the Norwegian laboratory
were not included for prevalence regression calculations, because
the cutoff concentrations used for blood samples were signif-
icantly higher than those used by the other participating labora-
tories (12).
Estimation of equivalent cutoff concentrations in blood
and oral ﬂuid
For each drug, the cohort of drug-positive cases was deﬁned as
individuals who had positive ﬁndings of the drug in question in
oral ﬂuid, blood or both. We studied the accuracy of three
methods for determining equivalent cutoff concentrations in
oral ﬂuid and blood: multiplying the cutoff concentration in
blood with the average or median OF/B ratio (12) and the use of
prevalence regression (15) to determine formulae deﬁning the
relations between the prevalence in samples of blood and
oral ﬂuid.
For prevalence regression, concentrations in oral ﬂuid corre-
sponding to the 40th, 45th, 50th, 55th, 60th, 65th, 70th, 75th,
80th, 85th, 90th and 95th percentiles were plotted against
the drug concentrations in blood corresponding to the same
percentiles. Outliers were not excluded when calculating the
percentiles. If only blood or oral ﬂuid was positive (i.e., the con-
centration was above the analytical cutoff), the other specimen
was given a concentration of zero for the prevalence regression
calculations.
If any of the lower percentile concentrations were lower than
the analytical cutoff concentration for either oral ﬂuid or blood
used by any of the participating laboratories, those percentiles
were deleted from the analysis.
Regression curve equations were determined using the ‘trend-
line’ function in Microsoft Excel. Linear, exponential, quadratic
and power functions were calculated, and the regression
formula with highest correlation coefﬁcient was selected for
each drug. The obtained formula thus described the relationship
between equivalent concentration percentiles in oral ﬂuid and
blood. Thereby, the prevalence (or percentile) of drug concen-
trations above a given cutoff threshold in blood would be equal
to that of drug concentrations in oral ﬂuid above a concentration
calculated by using the regression formulae.
For each drug, the accuracy for the determination of preva-
lence above low, medium and high concentration thresholds
were studied for the three estimation methods. As low thresh-
olds, the cutoff concentrations for blood used in the European
project ‘Driving under the Inﬂuence of Drugs, Alcohol and
Medicines’ (DRUID) (16) and recommendations from an inter-
national expert meeting (27) were selected. The high concen-
tration thresholds were selected so that 10–15% of the found
drug concentrations in the analyzed samples were above this
threshold, and the medium concentration thresholds corre-
sponded to 50% of the high concentration thresholds.
Differences between estimated and actual drug prevalence
above the low, medium and high concentration thresholds for
the three estimation methods were analyzed using a Student’s
t-test.
Approximate 95% conﬁdence intervals (95% CIs) for cutoff
concentrations in oral ﬂuid that were equivalent to the low
cutoff threshold for blood were estimated by ﬁrst calculating the
95% CI quantiles p using the Wald method (28): p ¼ p0+
1.96.[p0 (12 p0)/n]
1
2, where p0 is the prevalence (percentile) of
blood concentrations above the low cutoff threshold, and then
calculating the drug concentrations in oral ﬂuid corresponding
to the quantiles p using the formula that gave the best accuracy.
Results
In total, alprazolam was detected in samples of blood and/or
oral ﬂuid from 106 subjects, amphetamine 86, clonazepam 57,
cocaine 112, codeine 92, diazepam 94, methamphetamine 55,
morphine 76, nordiazepam 130, oxazepam 55, THC 182 and tra-
madol in 51 subjects.
The accuracy obtained when using the three methods for de-
termining equivalent cutoff concentrations in oral ﬂuid and
blood are presented in Table I. Prevalence regression gave
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the best accuracy for all drugs studied except for morphine;
statistically signiﬁcant differences were found when studying
the absolute values of the deviations from actual prevalence for
prevalence regression compared with using the average or
median multiplications (P, 0.001). The results thus indicate
that prevalence regression is the most robust method for the de-
termination of equivalent cutoff concentrations in oral ﬂuid and
blood. Examples of prevalence regression curves are presented
in Figure 1.
The estimated cutoff concentrations in oral ﬂuid equivalent
to those used for blood in the DRUID project are presented in
Table II together with 95% CI and the best ﬁtting formulae for
estimating equivalent cutoff concentrations.
The accuracy of the best ﬁtting formulae was also studied by
comparing the actual prevalence of drug concentrations above
the low cutoff concentrations in blood from the studied cohort
of 4,080 subjects with estimated prevalence including 95% CI
based on the analysis of oral ﬂuid. Results are presented in
Table III. For clonazepam and diazepam, the CIs could not be cal-
culated because the lower 95% CI concentration was below the
quantiﬁcation limits of the analytical methods. The accuracy was
good and the 95% CI acceptable.
Discussion
Previous studies using the same paired samples of oral ﬂuid
and blood as those used in this study found that the concen-
trations in oral ﬂuid cannot be used to accurately estimate the
drug concentration in blood for individuals because of large
variations in concentration ratios between oral ﬂuid and blood
(12, 13). However, other studies have found that when
Table I
Comparison of the accuracy for estimated equivalent cutoff concentrations in oral fluid
Substance (number of cases) Concentrations in
blood (ng/mL)
Actual prevalence
in blood (%)
Estimated prevalence in blood (and accuracy) using oral fluid (%)
PR AV ME
Alprazolam (n ¼ 106) 10 39.6 38.7 (20.9) 30.2 (29.4) 34.0 (25.6)
25 22.6 26.4 (þ3.8) 20.8 (21.8) 21.7 (20.9)
50 13.2 13.2 (þ0.0) 13.2 (þ0.0) 15.1 (þ1.9)
D ¼ 1.6 D ¼ 3.7 D ¼ 2.8
Amphetamine (n ¼ 86) 25 62.8 55.8 (27.0) 51.2 (211.6) 52.3 (210.5)
200 25.6 26.7 (þ1.1) 25.6 (þ0.0) 27.9 (þ2.3)
400 11.6 11.6 (þ0.0) 14.0 (þ2.4) 16.3 (þ4.7)
D ¼ 2.7 D ¼ 4.7 D ¼ 5.8
Clonazepam (n ¼ 57) 10 56.1 56.1 (þ0.0) 43.9 (212.2) 50.9 (25.2)
25 28.1 31.6 (þ3.5) 26.3 (21.8) 33.3 (þ5.2)
50 10.5 7.0 (23.5) 12.3 (þ1.8) 15.8 (þ5.3)
D ¼ 2.3 D ¼ 5.3 D ¼ 5.2
Cocaine (n ¼ 112) 10 23.2 23.2 (þ0.0) 23.2 (þ0.0) 24.1 (þ0.9)
40 16.1 17.9 (þ1.8) 10.7 (25.4) 10.7 (25.4)
80 13.4 10.7 (22.7) 8.0 (25.4) 8.0 (25.4)
D ¼ 1.5 D ¼ 3.6 D ¼ 3.9
Codeine (n ¼ 92) 10 31.5 33.7 (þ2.2) 31.5 (þ0.0) 46.7 (þ15.2)
20 23.9 21.7 (22.2) 19.6 (24.3) 28.3 (þ4.4)
40 14.1 12.0 (22.1) 9.8 (24.3) 15.2 (þ1.1)
D ¼ 2.2 D ¼ 2.9 D ¼ 6.9
Diazepam (n ¼ 94) 50 53.2 54.3 (þ1.1) 47.9 (25.3) 53.2 (þ0.0)
125 39.4 39.4 (þ0.0) 27.7 (211.7) 40.4 (þ1.0)
250 13.8 12.8 (21.0) 14.9 (þ1.1) 22.3 (þ8.5)
D ¼ 0.7 D ¼ 6.0 D ¼ 3.2
Methamphetamine (n ¼ 55) 25 70.9 72.7 (þ1.8) 72.7 (þ1.8) 74.5 (þ3.6)
300 36.4 32.7 (23.7) 27.3 (29.1) 30.9 (25.5)
600 14.5 12.7 (21.8) 12.7 (21.8) 20.0 (þ5.5)
D ¼ 2.4 D ¼ 4.2 D ¼ 4.9
Morphine (n ¼ 76) 10 42.1 36.8 (25.3) 36.8 (25.3) 44.7 (þ2.6)
20 18.4 25.0 (þ6.6) 25.0 (þ6.6) 31.6 (þ13.2)
40 13.2 10.5 (22.7) 15.8 (þ2.6) 21.1 (þ7.9)
D ¼ 4.9 D ¼ 4.8 D ¼ 7.9
Nordiazepam (n ¼ 130) 50 50.8 46.2 (24.6) 44.6 (26.2) 46.2 (24.6)
150 26.2 27.7 (þ1.5) 26.9 (þ0.9) 31.5 (þ5.3)
300 13.1 10.8 (22.3) 14.6 (þ1.5) 16.9 (þ3.8)
D ¼ 2.8 D ¼ 2.9 D ¼ 4.6
Oxazepam (n ¼ 55) 50 25.5 23.6 (21.9) 30.9 (þ5.4) 34.5 (þ9.0)
125 16.4 18.2 (þ1.8) 20.0 (þ3.6) 27.3 (þ10.9)
250 10.9 9.1 (21.8) 18.2 (þ7.3) 9.1 (þ9.1)
D ¼ 1.8 D ¼ 5.4 D ¼ 9.7
THC (n ¼ 182) 1.0 28.6 28.6 (20.0) 33.5 (þ4.9) 44.5 (þ15.9)
1.5 24.7 23.6 (21.1) 27.5 (þ2.8) 38.5 (þ13.8)
3.0 13.7 12.6 (21.1) 21.4 (þ7.7) 30.2 (þ16.5)
D ¼ 0.7 D ¼ 5.1 D ¼ 15.4
Tramadol (n ¼ 51) 25 35.3 33.3 (22.0) 31.4 (23.9) 33.3 (þ2.0)
100 23.5 23.5 (þ0.0) 29.4 (23.9) 19.6 (23.9)
200 11.8 13.7 (þ1.9) 5.9 (25.9) 9.8 (22.0)
D ¼ 1.3 D ¼ 4.6 D ¼ 2.6
Average deviation – – D ¼ 2.1 D ¼ 4.4 D ¼ 6.1
Deviations from actual prevalence are within parentheses and average of the absolute values of deviations is represented as D.
PR, prevalence regression; AV, multiplication of the concentrations in blood with the average OF/B concentration ratio; ME, multiplication with the median OF/B ratio (12).
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studying aggregated concentration data for a cohort, accept-
able accuracies on drug use in the cohort in total may be
obtained (14, 15), in spite of the fact that ﬁndings for single
individuals in the cohort may be incorrect. We expected that
the prevalence regression method would give the most accur-
ate calculations of equivalent cutoff concentrations, because
the skewness of the statistical distribution of OF/B ratios gives
a non-linear regression curve (15). The average OF/B ratio
may, however, be used as approximations for some drugs or
for limited concentration intervals for other drugs, as previous-
ly found for amphetamine and THC (14), albeit the estimated
prevalence of high drug concentrations in blood may be
inaccurate when using the average (14). It is also expected
that the accuracy of the estimation is related to the number
of subjects in the studied cohort due to large interindividual
variations; the larger the number of individuals, the better the
accuracy.
Previously, multiplication of the cutoff concentration in blood
with the slope of the linear regression between oral ﬂuid and
blood has also been suggested as a method for estimating the
equivalent cutoff in oral ﬂuid. However, single extreme values
have a large effect on the calculated coefﬁcient, and initial calcu-
lations using the data presented in this study indicated that the
accuracy therefore was poor (results not shown).
Figure 1. Prevalence regression curves for alprazolam, amphetamine, codeine and THC. Every 5th percentile from the 40th to the 95th is plotted, except for percentiles
corresponding to concentrations below the analytical cutoff concentrations for the analytical methods.
Table II
Estimated equivalent cutoff concentrations in blood and oral fluid, formulae, and coefficients of determination
Substance Cutoff in whole blood (ng/mL) Cutoff in oral fluida [95% CI] (ng/mL) Prevalence regression formulae R2
Alprazolam 10 2.8 [1.8–4.2] COF ¼ 0.013  CB2 – 0.25  CB þ 4 0.998
Amphetamine 20 290 [84–680] COF ¼ 0.034  CB2 þ 13.7  CB 0.993
Clonazepam 10 1.2 [0.2–2.0] COF ¼ 0:56 2:7180:079  CB 0.962
Cocaine 10 190 [26–350] COF ¼ 161 2:7180:019CB 0.932
Codeine 10 83 [50–130] COF ¼ 0.038  CB2 þ 4.2  CB þ 37 0.999
Diazepam 50 1.1 [0.3–3.6] COF ¼ 0.00024  CB2 þ 0.0089  CB 0.930
Methamphetamine 20 630 [120–1800] COF ¼ 0.033  CB2 þ 8.0  CB þ 891 0.993
Morphine 10 100 [37–180] COF ¼ 9.83  CB 0.902
Nordiazepam 50 2.2 [1.2–4.5] COF ¼ 0.000085  CB2 þ 0.040  CB 0.997
Oxazepam 50 12 [4.4–34] COF ¼ 0.235  CB 0.962
THC 1.0 44 [27–90] COF ¼ 44  CB1.4 0.991
Tramadol 50 490 [85–1500] COF ¼ 9.74  CB 0.966
COF, drug concentration in oral fluid; CB, drug concentration in blood.
aRounded to two significant digits.
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For all drugs except morphine, prevalence regression ﬁtted
the data better than using the mean or median OF/B ratios for
estimating equivalent cutoff concentrations in oral ﬂuid and
blood. This ﬁnding complies with the results of a previous study
of amphetamine and THC (15); however, the regression curves
were somewhat different, primarily because a different type of
oral ﬂuid collection device was used.
The 95% CI for estimated cutoff concentrations in oral ﬂuid
seems to be wide (Table II). However, due to the very wide dis-
tribution of drug concentrations in oral ﬂuid, the 95% CI for the
estimated prevalence in blood based on the analysis of oral ﬂuid
was acceptable as shown in Table III. For example, the 95% CI
for the cutoff for amphetamine in blood was 84–680 ng/mL,
which corresponded to an amphetamine prevalence of 1.0–
1.5% in the studied population (i.e., 1.5% had concentrations
above 84 ng/mL and 1.0% above 680 ng/mL in oral ﬂuid).
Results of preliminary estimations (29) were used in the
DRUID project to estimate cutoff concentrations in oral ﬂuid
that were equivalent to those used for blood. These data were
used when calculating the prevalence of drugs in blood and oral
ﬂuid samples from drivers in 13 European countries (7, 30). The
estimated cutoff concentrations for oral ﬂuid were based on a
smaller set of data, and linear regression lines were prioritized
whenever possible. In addition, estimated drug concentrations
below the analytical cutoff concentrations were included in the
original estimations; those were not included when calculating
the cutoff concentrations for oral ﬂuid presented in Table II.
Therefore, the results presented in this article are somewhat dif-
ferent for some substances, but probably more accurate.
When studying the prevalence of drugs in blood or oral ﬂuid
samples collected from a cohort, it is important to choose cutoff
concentrations that are relevant to what the intention is to
study, such as either any recent drug use (using a very low cutoff
concentrations) or drug use that may cause impairment (higher
cutoffs). Using alcohol as an analog, if the cutoff is 0.1 g/L for
alcohol, the prevalence of positive ﬁndings will be much higher
than if using a cutoff of 0.5 g/L, which is the legal limit for drunk
driving in most European countries.
The cutoff concentrations for blood presented in Table II
were primarily based on analytical capabilities and not on
pharmacological effects. The prevalence of drug concentrations
above those cutoff limits can therefore not be used to compare
different drugs regarding the prevalence of impairment or
misuse, neither if analyzing blood nor if analyzing oral ﬂuid
samples. An attempt was made to deﬁne drug concentration
cutoffs similar to a blood alcohol concentration of 0.2 g/L when
determining the Norwegian legal limits for driving under the in-
ﬂuence of drugs. Those drug concentration limits were either
deﬁned as one-ﬁfth of the maximum concentration in whole
blood observed after the use of ‘standard’ recreational and inebri-
ating drug doses or determined by assessing the impairment cor-
responding to an alcohol concentration of 0.2 g/L after single
drug doses in naive individuals (31).
The formulae presented in Table II may then be used to esti-
mate cutoff concentrations in oral ﬂuid collected with the
Statsure device that are equivalent to chosen cutoff concentra-
tions for blood. A limitation is that the formulae may not apply
for oral ﬂuid collected with other types of devices. The formulae
are not intended for the assessment of drug concentrations in
oral ﬂuid for single individuals due to the large interindividual
variation in OF/B ratios observed.
Another limitation of the study was that the formulae that ﬁtted
the original data best were regarded as the most accurate ones
without validating the formulae using data from an independent
cohort. No other large study has collected oral ﬂuid with the
Statsure device and simultaneously collected paired samples of
blood; therefore such a validation or comparison with other
cohorts could not be performed. We assume that such a study
would probably ﬁnd somewhat larger inaccuracies and wider 95%
CI for the estimated cutoff concentrations in oral ﬂuid.
The best option in cross-sectional studies and case–control
studies of drugs of abuse would be to avoid using more than one
type of biological matrix for drug analysis. In studies of
drug-related impairment and in case–controls studies of
drug-related risk for involvement in trafﬁc crashes, blood
samples should be the matrix of choice if it is possible to obtain
high participation rate. At present, this seems to be difﬁcult;
therefore, collection of blood from ‘cases’ and oral ﬂuid from
‘controls’ has been chosen in several studies. It is then important
to use equivalent cutoff concentrations for drugs in those two
matrices. In the future, the use of microsampling techniques for
blood (32) might become a better option than collecting oral
ﬂuid from controls if it is possible to obtain a higher participa-
tion rate than when using traditional blood sampling.
Acknowledgments
Thanks to the personnel at the participating universities and
institutes for the handling and analysis of samples of blood and
oral ﬂuid.
Funding
This study was in part supported by the European Commission
through the project ‘Driving Under the Inﬂuence of Drugs,
Alcohol and Medicines’ within the 6th Framework Program
(contract no. TREN-05-FP6TR-S07.61320-518404-DRUID).
Conflict of interest
This document reﬂects only the authors’ view. The European
Commission is not liable for any use that may be made of the in-
formation contained herein.
Table III
Actual and estimated prevalence (%) of blood drug concentrations above cutoffs in blood samples
from the studied cohort of 4,080 individuals using the best fitting formulae
Substance Actual prevalence above
cutoffs in blood
Estimated prevalence above cutoffs in blood
based on concentrations in oral fluid [95% CI]
Alprazolam 1.0 1.0 [0.8–1.3]
Amphetamine 1.3 1.3 [1.0–1.5]
Cocaine 0.6 0.7 [0.4–0.9]
Codeine 0.7 0.8 [0.5–1.0]
Methamphetamine 1.0 1.0 [0.8–1.2]
Morphine 0.8 0.7 [0.5–0.9]
Nordiazepam 1.6 1.5 [1.2–1.7]
Oxazepam 0.3 0.3 [0.2–0.5]
THC 1.2 1.3 [1.0–1.6]
Tramadol 0.4 0.4 [0.2–0.5]
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